Clinical trial NCT04436588: Better Delineation of DDX3X Related Phenotype and Epigenetic Signature.
Official title: DDX3X Related Disorder : Clinical Phenotype, Neuropsychological Profile and Epigenetic Signature.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Intellectual Developmental Disorder
X-LINKED
Keywords: DDX3X
Syndromic
SNIJDERS BLOK
Lead sponsor: University Hospital, Montpellier
Sponsor class: OTHER
Collaborators: name: Association Xtraordinaire sub-group DDX3X
name: Genida
First posted: 2020-06-18
Enrollment: 10
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Individuals with DDX3X pathogenic Variant

Brief summary: DDX3X related disorder is mainly characterised by developmental delay (DD) and intellectual disability (ID), ranging from mild to severe, and neuroimaging abnormalities.

The aims of this study are first to better delineate the clinical phenotype, as well as the neuropsychological profile and, second, to study the epigenetic signature in a cohort of individuals with DDX3X pathogenic variants. This work will conduct to a MD thesis of a clinical resident geneticist in France.

Physician that will participate will fill an Excel sheet regarding the clinical and neuropsychological assessment. The investigators will be also happy to have a DNA sample with a minimum 0.5ug of peripheral blood genomic DNA. The investigators will gather the DNA in Montpellier genetic lab (Dr Mouna BARAT) and send the batch to the Dr Sadikovic' lab.

Between 2018 and 2020, the investigators have already recruited data from individuals with DDX3X pathogenic variants from several European and Asian genetic centres

Detailed description: The investigators aim to better understand and delineate the genetic syndrome DDX3X.

This genetic disorder was described in 2015 by Lot Snijders Blok et al. (DOI https://doi.org/10.1016/j.ajhg.2015.07.004:).

Since this first publication of 38 female individuals carrying a pathogenic mutation DDX3X, 15 more individuals have been reported.

The investigators are seeking to better define the phenotype of individuals with pathogenic variants of DDX3X, to better understand intellectual functioning as well as the strengths and weaknesses of intellectual functioning by collecting standardized neuropsychological assessments already performed such as WPPSI/WISC and WAIS. For this purpose, the investigators will gather clinical and neuropsychological data already carried out in the context of care.

Finally, the investigators will attempt to identify an epigenetic signature in this genetic disease. To this end, the investigators will collect genomic DNA from peripheral blood already collected for genetic analysis and send an anonymized batch of samples to our collaborator, Dr. Bekim Sadicovik. Dr. Bekim Sadicovik and his team will compare the epigenetic DNA methylation-type markers with the corresponding sex and age controls. If specific probes are abnormally methylated in DDX3X individuals, this will determine a disease-specific epigenetic signature. The investigators will then be able to propose an epigenetic signature for individuals with uncharacterized DDX3X variations (class 3, VUS). This method will make it possible to define whether the variation is responsible for the disease or not without going through functional analysis steps that are difficult to implement routinely.

The expected benefits are a better understanding of DDX3X disease, keys to neuropsychological rehabilitation, a better understanding of human brain functions, the possibility of proposing an epigenetic signature for people in whom it is not possible to decide whether a variation in the DDX3X gene is pathological or not

Eligibility criteria: Inclusion criteria:

- DDX3X pathogenic Variant

Exclusion criteria:

* no pathogenic variant in DDX3X
* no consent for the study

Primary outcomes:
measure: Neuropsychological phenotype will be assessed using Wechsler scales
timeFrame: 1 day
measure: Measurement and comparison of the methylation of the cpg sites"
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Montpellier
country: France
facility: UH Montpellier
Study officials:
affiliation: Department of Medical Genetics
name: David GENEVIEVE
role: PRINCIPAL_INVESTIGATOR
References: